SEC Comment Letter for Emergent BioSolutions Inc. (EBS) (CIK 0001367644) (EBS) — Mar 5, 2019

Emergent BioSolutions Inc. (EBS) (CIK 0001367644)
Date: March 5, 2019 · CIK: 0001367644 · Accession: 0000000000-19-003920

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-33137

Date

March 5, 2019

Author

Richard S. Lindahl

Form

UPLOAD

Company

Emergent BioSolutions Inc. (EBS) (CIK 0001367644)

Letter

March 5, 2019 Richard S. Lindahl Executive Vice President and Chief Financial Officer Emergent BioSolutions Inc. 400 Professional Drive Suite 400 Gaithersburg, MD 20879 Re:Emergent BioSolutions Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed February 23, 2018 File No. 001-33137 Dear Mr. Lindahl: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

March 5, 2019
Richard S. Lindahl
Executive Vice President and Chief Financial Officer
Emergent BioSolutions Inc.
400 Professional Drive
Suite 400
Gaithersburg, MD 20879
Re:Emergent BioSolutions Inc.
Form 10-K for the Fiscal Year Ended December 31, 2017
Filed February 23, 2018
File No. 001-33137
Dear Mr. Lindahl:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io